Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

42.75 +0.22 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 401,240
Open 42.42
Bid (Size) 40.41 (1)
Ask (Size) 42.96 (7)
Prev. Close 42.53
Today's Range 41.99 - 43.33
52wk Range 15.50 - 52.57
Shares Outstanding 60,972,909
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-5.27%
-5.27%
1 Month
+18.06%
+18.06%
3 Month
+8.15%
+8.15%
6 Month
-11.03%
-11.03%
1 Year
+143.87%
+143.87%

More News

Read More
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
The 3 Best Nasdaq Stocks to Buy in May 2024
Via InvestorPlace
Preview: Rhythm Pharmaceuticals's Earnings
Via Benzinga
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
Via Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For February 22, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.